CureVac (NASDAQ:CVAC) Price Target Lowered to $12.00 at UBS Group

CureVac (NASDAQ:CVAC - Get Free Report) had its price objective decreased by research analysts at UBS Group from $13.00 to $12.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the stock. UBS Group's target price indicates a potential upside of 229.22% from the company's current price.

Separately, JMP Securities restated a "market outperform" rating and issued a $16.00 price objective on shares of CureVac in a report on Friday, February 14th.

CureVac Trading Up 3.3 %

CureVac stock traded up $0.12 during mid-day trading on Wednesday, hitting $3.65. 150,618 shares of the company's stock were exchanged, compared to its average volume of 798,157. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. CureVac has a fifty-two week low of $2.37 and a fifty-two week high of $5.28. The company's 50 day simple moving average is $3.05 and its 200-day simple moving average is $3.18. The firm has a market capitalization of $817.71 million, a P/E ratio of 6.64 and a beta of 2.48.

CureVac (NASDAQ:CVAC - Get Free Report) last issued its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $15.44 million during the quarter, compared to analyst estimates of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, equities analysts anticipate that CureVac will post 0.72 earnings per share for the current year.

Institutional Investors Weigh In On CureVac

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC bought a new position in shares of CureVac in the third quarter worth $67,000. Jane Street Group LLC raised its stake in shares of CureVac by 239.0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock valued at $235,000 after acquiring an additional 55,867 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in CureVac by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company's stock valued at $162,000 after purchasing an additional 4,425 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in CureVac by 61.8% in the fourth quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company's stock worth $171,000 after acquiring an additional 19,098 shares during the period. Finally, Signaturefd LLC increased its position in shares of CureVac by 29.2% during the fourth quarter. Signaturefd LLC now owns 36,140 shares of the company's stock valued at $123,000 after buying an additional 8,170 shares during the period. 17.26% of the stock is currently owned by institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.